Literature DB >> 8996601

Preclinical and clinical development of camptothecins.

D Costin1, M Potmesil.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 8996601     DOI： 10.1016/s1054-3589(08)61131-x

Source DB:  PubMed          Journal:  Adv Pharmacol        ISSN： 1054-3589


× No keyword cloud information.
  5 in total

1.  A eukaryotic enzyme that can disjoin dead-end covalent complexes between DNA and type I topoisomerases.

Authors:  S W Yang; A B Burgin; B N Huizenga; C A Robertson; K C Yao; H A Nash
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-15       Impact factor: 11.205

Review 2.  Clinical pharmacokinetics of topotecan.

Authors:  V M Herben; W W ten Bokkel Huinink; J H Beijnen
Journal:  Clin Pharmacokinet       Date:  1996-08       Impact factor: 6.447

Review 3.  Camptothecins: a review of their chemotherapeutic potential.

Authors:  Hulya Ulukan; Peter W Swaan
Journal:  Drugs       Date:  2002       Impact factor: 9.546

4.  Molecular and cytotoxic effects of camptothecin, a topoisomerase I inhibitor, on trypanosomes and Leishmania.

Authors:  A L Bodley; T A Shapiro
Journal:  Proc Natl Acad Sci U S A       Date:  1995-04-25       Impact factor: 11.205

5.  Phase I study of nanoliposomal irinotecan (PEP02) in advanced solid tumor patients.

Authors:  T C Chang; H S Shiah; C H Yang; K H Yeh; A L Cheng; B N Shen; Y W Wang; C G Yeh; N J Chiang; J Y Chang; L T Chen
Journal:  Cancer Chemother Pharmacol       Date:  2015-01-11       Impact factor: 3.333
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.